Literature DB >> 22315722

Inflammation and adaptive immunity in Parkinson's disease.

R Lee Mosley1, Jessica A Hutter-Saunders, David K Stone, Howard E Gendelman.   

Abstract

The immune system is designed to protect the host from infection and injury. However, when an adaptive immune response continues unchecked in the brain, the proinflammatory innate microglial response leads to the accumulation of neurotoxins and eventual neurodegeneration. What drives such responses are misfolded and nitrated proteins. Indeed, the antigen in Parkinson's disease (PD) is an aberrant self-protein, although the adaptive immune responses are remarkably similar in a range of diseases. Ingress of lymphocytes and chronic activation of glial cells directly affect neurodegeneration. With this understanding, new therapies aimed at modulating the immune system's response during PD could lead to decreased neuronal loss and improved clinical outcomes for disease.

Entities:  

Mesh:

Year:  2012        PMID: 22315722      PMCID: PMC3253034          DOI: 10.1101/cshperspect.a009381

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  189 in total

1.  Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia.

Authors:  W G Kim; R P Mohney; B Wilson; G H Jeohn; B Liu; J S Hong
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Alterations of T-lymphocyte populations in Parkinson disease.

Authors:  Yasuhiko Baba; Ataru Kuroiwa; Ryan J Uitti; Zbigniew K Wszolek; Tatsuo Yamada
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

Review 3.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

4.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

5.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

6.  Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system.

Authors:  Jonathan Kipnis; Tal Mizrahi; Ehud Hauben; Iftach Shaked; Ethan Shevach; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

Review 7.  The concept of microglia in relation to central nervous system disease and regeneration.

Authors:  S Moore; S Thanos
Journal:  Prog Neurobiol       Date:  1996 Mar-Apr       Impact factor: 11.685

8.  Anti-neurofilament antibodies in blood of patients with neurological diseases.

Authors:  D Karcher; B S Federsppiel; F D Lowenthal; F Frank; A Lowenthal
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

Review 9.  Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease.

Authors:  Milan Fiala; Robert Veerhuis
Journal:  Exp Gerontol       Date:  2009-08-21       Impact factor: 4.032

10.  Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function.

Authors:  S Elkabes; E M DiCicco-Bloom; I B Black
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

View more
  106 in total

1.  In search of an immunobiomarker for Parkinson's disease.

Authors:  Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-09       Impact factor: 4.147

Review 2.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

3.  Pink Light on Mitochondria in Autoimmunity and Parkinson Disease.

Authors:  Adriana R Mantegazza; Michael S Marks
Journal:  Cell Metab       Date:  2016-07-12       Impact factor: 27.287

4.  SIRT3 Acts as a Neuroprotective Agent in Rotenone-Induced Parkinson Cell Model.

Authors:  Jing-Yi Zhang; Yong-Ning Deng; Meng Zhang; Hua Su; Qiu-Min Qu
Journal:  Neurochem Res       Date:  2016-04-06       Impact factor: 3.996

5.  Phenome-based gene discovery provides information about Parkinson's disease drug targets.

Authors:  Yang Chen; Rong Xu
Journal:  BMC Genomics       Date:  2016-08-31       Impact factor: 3.969

Review 6.  Inflammation in neurodegenerative diseases--an update.

Authors:  Sandra Amor; Laura A N Peferoen; Daphne Y S Vogel; Marjolein Breur; Paul van der Valk; David Baker; Johannes M van Noort
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

7.  Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats.

Authors:  Sadaf Naeem; Rahila Najam; Saira Saeed Khan; Talat Mirza; Bushra Sikandar
Journal:  Metab Brain Dis       Date:  2019-05-04       Impact factor: 3.584

Review 8.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

Review 9.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

Review 10.  Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.

Authors:  Katherine E Olson; Howard E Gendelman
Journal:  Curr Opin Pharmacol       Date:  2015-11-11       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.